BCR and neoplasm: The underlying mechanisms of imatinib resistance could be a result of point mutations in the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) kinase domain, amplification of the BCR-ABL gene, and overexpression of the multidrug resistance protein 1 (MRP1) gene in tumor cells [96, 97].